ASCO American Society of Clinical Oncology
- Start Date:
29 May 2026
- End Date:
02 Jun 2026
- Location:
Chicago, IL
- Region:
North America
- Booth #:
30131
Thermo Fisher Scientific is proud to be an exhibitor at the ASCO Annual Meeting 2026
For more than 30 years, our CRO solutions have enabled drug developers to develop and commercialize their oncology treatments. Success in oncology clinical research requires a provider of CRO solutions with a deep understanding of the disease and an unrelenting dedication to developing the services that patients need. In the past five years alone, our team has supported 34 oncology drug approvals in the U.S. — including three first-in-class products — and 25 EMEA approvals.
Precision oncology and next-generation sequencing
A precision medicine approach to cancer therapeutics is a biomarker-driven strategy with a laser focus on delivering therapies to the right patients at the right time. This is why predictive biomarker testing has become the basis for selecting appropriate precision therapies for cancer patients. It has helped to transform cancer treatment, which has evolved dramatically over the past 25 years.
We have brought precision medicine capabilities to community sites, empowering them to be an end-to-end solution for our clients. We do so with innovations like Oncomine Solutions, our in-house, high-speed genomic profiling solutions. Oncomine Solutions enable sponsors to solve many of the most common issues faced by precision medicine therapeutics development while allowing for elevated global data into genomic profiling for better study feasibility and site strategy.
Oncomine™ Solutions — the latest technology for fast-profiling and next-generation sequencing of key biomarkers and comprehensive genomic profiling — provides molecular insights to inform the most critical decisions with speed and accuracy.
Accelerating first-in-human and early phase oncology trials
We are a leader of early phase CRO solutions with decades of oncology expertise and more than 250 early phase oncology studies conducted in the past five years.
We combine therapeutic depth with agile processes, along with a team specifically aligned with a biotech’s expectations.
Our experts in regulatory science, clinical operations, biostatistics and data management don’t just consult — they embed into your team, offering adaptive strategies tailored to your molecule, goals and timelines.
You can rely on us as an experienced early phase oncology partner for your study. Whether advancing your first-in-human trial or managing complex Phase I/II programs, we provide unparalleled support to accelerate your oncology drug development at every step.
Enhancing clinical efficiency through master protocol trial design
The application of innovative oncology trial designs — such as adaptive designs and master protocols — can have a big impact in early phase oncology trials when decisions have far-reaching consequences.
We are experts in innovative adaptive clinical trial designs and master protocols. In the past five years, our expert master protocol/complex clinical trial team has supported:
Master protocol /
complex clinical trials
Patients
Indications
Countries
Global sites
Our proven oncology experience designing and operationalizing adaptive and other innovative clinical trial designs, through our Adaptive Design and Master Protocol Working Group, enables you to unlock better information, faster.
Schedule a meeting or stop by our booth (#30131) to learn more about our commitment to developing novel therapies that more effectively treat cancer.
